POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial. Randomization phase of SPLASH trial ongoing, top line data expected mid-2023. Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022. Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses of PNT2002 to support the SPLASH trial – view the facility online at manufacturing.pointbiopharma.com.